Although our study has certain limitations and only 14% of EMPD cases in our study had tumor cells positive for PD-L1, clinical trials of immune checkpoint inhibitors in EMPD might prove beneficial, especially in patients with metastatic EMPD. This evidence concerns the gene CD274 and neoplasm.